Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
139.31B
Market cap139.31B
Price-Earnings ratio
22.05
Price-Earnings ratio22.05
Dividend yield
2.81%
Dividend yield2.81%
Average volume
7.21M
Average volume7.21M
High today
$112.65
High today$112.65
Low today
$111.10
Low today$111.10
Open price
$111.37
Open price$111.37
Volume
6.54M
Volume6.54M
52 Week high
$121.83
52 Week high$121.83
52 Week low
$81.83
52 Week low$81.83

GILD News

TipRanks 2d
Buy Recommendation for Gilead Sciences Amid Strategic Positioning and Legal Developments

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences and keeping the price target at $143.00. Elevate Your Investing Strategy: T...

Simply Wall St 3d
What Gilead Sciences's Global HIV Partnership and US Manufacturing Expansion Means for Shareholders

In early September 2025, Gilead Sciences announced a partnership with the U.S. State Department and PEPFAR to expand access to its twice-yearly injectable HIV-1...

What Gilead Sciences's Global HIV Partnership and US Manufacturing Expansion Means for Shareholders
Simply Wall St 6d
Gilead Sciences Commits To Veeva Systems For Vault CRM Suite

recently announced that Gilead Sciences has committed to using its Veeva Vault CRM, highlighting the company's expansion in the pharmaceutical CRM space through...

Gilead Sciences Commits To Veeva Systems For Vault CRM Suite

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.